Related Experiment Videos
Myasthenia gravis during interferon alfa therapy
A P Batocchi1, A Evoli, S Servidei
1Institute of Neurology, Catholic University, Rome, Italy.
Neurology
|February 1, 1995
Summary
Interferon alfa treatment can trigger autoimmune responses, including myasthenia gravis. This study details two cases of patients developing this condition and related antibodies during interferon alfa-2b therapy.
Area of Science:
- Immunology
- Neurology
- Oncology
Background:
- Interferon alfa is a therapeutic agent used in treating various malignancies.
- Patients undergoing interferon alfa therapy are at risk for developing autoantibodies and autoimmune conditions.
- Autoimmune diseases can manifest during or after treatment with interferon alfa.
Observation:
- Two patients developed myasthenia gravis during treatment with interferon alfa-2b for malignancies.
- Both patients exhibited abnormal levels of serum anti-acetylcholine receptor antibodies.
- One patient presented with electromyography (EMG) myopathic findings and focal cytochrome c oxidase deficiency on muscle biopsy.
Findings:
- Interferon alfa-2b therapy was associated with the onset of myasthenia gravis in these patients.
- Elevated anti-acetylcholine receptor antibodies indicate an autoimmune attack on neuromuscular junctions.
- Muscle biopsy revealed specific pathological changes in one patient, correlating with the neurological condition.
Implications:
- This highlights a potential adverse effect of interferon alfa-2b therapy, necessitating careful patient monitoring.
- Early recognition of autoimmune phenomena in patients on interferon alfa is crucial for timely intervention.
- Understanding this association may inform risk-benefit assessments for interferon alfa treatments in cancer patients.